drugset / Trial / NCT03119194

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067

NCT03119194

Phase 1 Completed 7 enrolled Bial - Portela C S.A.
NaSingle-groupOpen-labelTreatment

Summary

The purpose is to and to assess the mass balance recovery after a single oral dose of \[14C\]-BIA 9-1067 and to provide plasma, urine and faecal samples for metabolite profiling and structural identification.

Timeline

Start
2017-01-27
Primary completion
2017-04-27
Completion
2017-04-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Opicapone Small molecule 100 mg Oral

Indications